Precision Medicine Is Precisely Right Theme For Biopharma: Impact Of Therapy—Not Cost—Is Focus
This article was originally published in RPM Report
A Senate hearing on President Obama’s Precision Medicine initiative illustrates how well that theme plays for the biopharma sector. The focus was on the potential for highly effective targeted therapies to help patients—and even lower costs for the system. The price of the drugs themselves was not even raised.
You may also be interested in...
Sen. Warren’s “War on Pharma”: Rhetorical Blast, But Remarkably Limited Objectives
Despite her reputation as a populist, anti-corporate crusader, Elizabeth Warren did not focus on Big Pharma in her first years in the Senate. The headlines following a speech by Warren last week suggest that has changed – but the actual legislative proposal looks a lot different than the rhetoric makes it sound.
Third Time’s A Charm? US FDA Once Again Proposes Mandatory Consumer Rx Info
The US Food & Drug Administration is once again proposing a mandatory summary of key labeling information be dispensed with every prescription drug. Will the idea stay on the books this time?
Survey Or Shakedown? US Medicaid’s Audacious Negotiation Plan
The US Medicaid program is proposing what amounts to a price negotiation program by using a survey/audit authority as a 'stick' to encourage manufacturers to offer supplemental rebates or outcomes-based contracts. Is it an offer sponsors can’t refuse?